Last reviewed · How we verify

NCT05791786: AFE

The Establishment of a Registry and a Biorepository of Patients With Suspected Amniotic Fluid Embolism (AFE)

Recruiting now Last updated 6 December 2024
What this trial tests

trial testing Patient in Amniotic Fluid Embolism in 400 participants. Currently enrolling.

Timeline
5 July 2022
Primary endpoint
1 October 2031
31 December 2031

Quick facts

Lead sponsorThe University of Texas Health Science Center, Houston
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment400
Start date5 July 2022
Primary completion1 October 2031
Estimated completion31 December 2031
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

The University of Texas Health Science Center, Houston

Who can join

Eligibility, any sex, with Amniotic Fluid Embolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To establish a clinical registry of suspected cases of AFE. The existing registry will be migrated to a new platform,

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Patient

Trials testing the same drug.

Other The University of Texas Health Science Center, Houston trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05791786.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing